A

Actinium Pharmaceuticals
D

ATNM

1.45000
USD
-0.01
(-0.68%)
مغلق
حجم التداول
696
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
45,234,042
أصول ذات صلة
A
ARWR
-0.120
(-0.71%)
16.790 USD
C
CLLS
-0.05000
(-3.05%)
1.59000 USD
C
CRSP
0.455
(0.88%)
52.120 USD
E
EDIT
0.02000
(0.78%)
2.57000 USD
F
FATE
0.02000
(1.80%)
1.13000 USD
G
GERN
0.02500
(1.78%)
1.43000 USD
I
INO
-0.71500
(-33.49%)
1.42000 USD
N
NTLA
-0.020
(-0.19%)
10.710 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
S
SGMO
0.00200
(0.38%)
0.53200 USD
المزيد
الأخبار المقالات

العنوان: Actinium Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.